GlassScriptPhysician profile
James K Andrews
NPI 1982690129
$11,260.33
in general payments reported to CMS, 2019-2025
54 companies · $907 in 2025
The $907 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,629 · 2020: $1,204 · 2021: $1,714 · 2022: $2,150 · 2023: $2,184 · 2024: $1,472 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,562.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,138.98 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,049.12 | 2019-2025 | Evenity, Prolia, Otezla |
| Novo Nordisk INC | $976.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $842.21 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $765.35 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $765.32 | 2019-2025 | Breztri, Airsupra, Nexium |
| Abbvie INC. | $697.62 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Merck Sharp & Dohme LLC | $541.59 | 2019-2024 | Verquvo, Belsomra, Capvaxive |
| Janssen Pharmaceuticals, INC | $507.92 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $470.72 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $438.64 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astellas Pharma US INC | $416.95 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $275.64 | 2019-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $185.63 | 2021-2023 | |
| Radius Health, INC. | $180.15 | 2019-2025 | Tymlos |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $178.66 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $167.30 | 2019-2022 | |
| Abbott Laboratories | $139.18 | 2019-2024 | Octrode |
| Eisai INC. | $130.27 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $121.24 | 2022-2024 | Eliquis |
| Daiichi Sankyo INC. | $98.94 | 2019-2024 | Injectafer |
| Allergan, INC. | $83.61 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $74.53 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $68.98 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ironwood Pharmaceuticals, INC | $67.28 | 2019-2020 | |
| Dexcom, INC. | $65.72 | 2022-2023 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $61.98 | 2020-2021 | |
| Nevro Corp. | $57.12 | 2023 | Senza |
| Sunovion Pharmaceuticals INC. | $49.02 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $47.86 | 2021 | |
| Amarin Pharma, INC. | $47.56 | 2019-2020 | |
| Vbi Vaccine (Delaware) INC. | $43.37 | 2022-2023 | Prehevbrio |
| Otsuka America Pharmaceutical, INC. | $43.07 | 2023-2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $34.99 | 2022 | |
| Si-Bone, INC. | $34.50 | 2024 | |
| Antares Pharma, INC. | $33.85 | 2019-2020 | |
| Cordis US Corp. | $33.35 | 2025 | Mynx Control Venous |
| Ibsa Pharma INC. | $31.19 | 2021-2024 | Tirosint, Licart |
| Teva Pharmaceuticals USA, INC. | $27.96 | 2021-2022 | |
| Sanofi Pasteur INC. | $24.67 | 2025 | |
| Averitas Pharma INC. | $23.84 | 2023 | Qutenza |
| Cequr Corporation | $23.01 | 2023 | Cequr Simplicity |
| Xeris Pharmaceuticals, INC. | $22.06 | 2022 | |
| Corium, LLC | $21.48 | 2023 | Adlarity |
| Corcept Therapeutics | $19.85 | 2025 | Korlym |
| Inari Medical, INC. | $17.69 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Adlon Therapeutics L.P. | $16.37 | 2020 | |
| Idorsia Pharmaceuticals US INC | $15.76 | 2022 | |
| Sumitomo Pharma America, INC. | $14.65 | 2023 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $14.65 | 2023 | Nuzyra |
| Genentech USA, INC. | $14.55 | 2021 | |
| Cmp Pharma, INC. | $13.20 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.